SavedAdd your journal

Journals / Medical Records / 2023 / Cilt: 5 Sayı: 3

Second Allogeneic Stem Cell Transplantation in Acute Leukemia with Post-Transplantation Relapse

Zeynep Tuğba GÜVEN
Serhat ÇELİK
Bülent ESER
Mustafa ÇETİN
Ali ÜNAL
Leylagül KAYNAR
Pages
455–9
Publication Date
2023-09-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After the second ASCT, overall survival (OS) was 6.34 months, and leukemia-free survival (LFS) was 13.8 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: It is known that the prognosis of acute leukemia patients who relapse after the first allogeneic stem cell transplantation (ASCT) is dismal.
📊
Key Findings & Data:Material and Methods: We retrospectively reviewed data from 29 patients with relapsing acute leukemia who underwent a second ASCT.
💡
Conclusion & Impact:After the second ASCT, overall survival (OS) was 6.34 months, and leukemia-free survival (LFS) was 13.8 months.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Post transplantation relapse · second transplantation · acute leukemia

Abstract

Aim: It is known that the prognosis of acute leukemia patients who relapse after the first allogeneic stem cell transplantation (ASCT) is dismal. Our goal was to assess the value of a second allogeneic stem cell transplant in acute leukemia patients who experienced post-transplant recurrence. Material and Methods: We retrospectively reviewed data from 29 patients with relapsing acute leukemia who underwent a second ASCT. Nineteen patients with acute myeloid leukemia and ten patients with acute lymphoblastic leukemia were included in the study. Results: Ten AML patients and 10 ALL patients were included in the study. Most patients (62%) were in remission before the second transplantation. The median time between the first and second ASCT was 11.9 months (3.1-42 months). Complete remission (CR) was achieved after the second ASCT in 21 (72%) patients, and 11 (52%) patients relapsed after the second ASCT. During this analysis, six patients (21%) were alive and in remission. Relapse of the disease was the leading cause of mortality. After the second ASCT, overall survival (OS) was 6.34 months, and leukemia-free survival (LFS) was 13.8 months. Conclusion: For patients with acute leukemia who relapsed after the first ASCT, a second ASCT is a good option and can keep patients alive.

🔖

Cite This Article

GÜVEN, Z. T., ÇELİK, S., ESER, B., ÇETİN, M., ÜNAL, A., KAYNAR, L. (2023). Second Allogeneic Stem Cell Transplantation in Acute Leukemia with Post-Transplantation Relapse. Medical Records, Cilt: 5 Sayı: 3, 455–9. https://ajindex.com/articles/962241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplantation. 2013;48:537-43.
  2. Ozdemir ZN, Bozdağ SC. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57:163-7.
  3. Schneidawind C, Hagmaier V, Faul C, et al. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. J Annals of Hematol. 2018;97:2491-500.
  4. Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell ransplantation. J Biology of Blood. 2013;19:1713-8.
  5. Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. Jama Oncol. 2018;4:1245-53.
  6. Ruutu T, De Wreede L, Van Biezen A, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015;50:1542-50. Weisdorf DJBp. The role of second transplants for leukemia. Best Pract Res Clin Haematol. 2016;29:359-64.
  7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649-56.
  8. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (hct)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. 2005;106:2912-9.
  9. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel. Blood. 2017;129:424-47.
  10. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33.
  11. Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute gvhd international consortium. Biol Blood Marrow Transplant. 2016;22:4-10.
  12. Pavletic SZ, Vogelsang GB, Lee SJ. 2014 national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: preface to the series. Biol Blood Marrow Transplant. 2015;21:387-8.
  13. Hosing C, Saliba R, Shahjahan M, et al. Disease burden may identify patients more likely to benefit from second allogeneic